Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: Results from the OSCAR Study Group

Valentina Svicher, Roberta D'Arrigo, Claudia Alteri, Massimo Andreoni, Gioacchino Angarano, Andrea Antinori, Guido Antonelli, Patrizia Bagnarelli, Fausto Baldanti, Ada Bertoli, Marco Borderi, Enzo Boeri, Isabella Bonn, Bianca Bruzzone, Anna Paola Callegaro, Roberta Cammarota, Filippo Canducci, Francesca Ceccherini-Silberstein, Massimo Clementi, Antonella D Arminio MonforteAndrea De Luca, Antonio Di Biagio, Simona Di Gianbenedetto, Giovanni Di Peni, Massimo Di Pietro, Lavinia Fabeni, Giovanni Fadda, Massimo Galli, William Gennari, Valeria Ghisetti, Andrea Giacometti, Andrea Gori, Francesco Leoncini, Franco Maggiolo, Renato Maserati, Francesco Mazzotta, Valeria Micheli, Genny Meini, Laura Monno, Cristina Mussini, Silvia Nozza, Stefania Paolucci, Saverio Parisi, Monica Pecorari, Daniele Pizzi, Tiziana Quirino, Maria Carla Re, Giuliano Rizzardini, Rosaria Santangelo, Alessandro Soria, Francesca Stazi, Gaetana Sterrantino, Ombretta Turriziani, Claudio Viscoli, Vincenzo Vullo, Adriano Lazzarin, Cario Federico Perno

Research output: Contribution to journalArticle

Abstract

Objective: The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in clinical practice using the enhanced sensitivity version of Trafile (ESTA) as reference-assay. Methods: HIV-1 coreceptor-usage was assessed using plasma samples from 406 HIV-1 infected patients by ESTA and by gp120 V3 population-sequencing followed by Geno2pheno (set at a False Positive Rate [FPR] of 10% and 5%). Results: ESTA was successful in 365 (89.9%) samples indicating R5 in 254 (69.6%), and DM/X4 in 111 (30.4% of samples (104 [28.5%] DM and 7 [1.9%] X4). Genotypic-testing successfully assessed viral tropism for all 406 samples, including the 41 with undetermined result by ESTA. Genotypic-tropism testing at a FPR of 5% and 10% was 81.1% and 78.4% concordant with ESTA, respectively. Despite a sensitivity of 48.7% and 55.9% at a FPR of 5% and 10%, respectively, a high concordance (specificity: 95.3% for FPR of 5% and 88.2% for FPR of 10%) between genotypic-tropism testing and ESTA was reached in the detection of R5-tropic viruses. Conclusion: Our results are in line with other European studies, and support the routine use of genotypic tropism testing in clinical-settings for monitoring of HIV-1 infected patients candidate to or failing CCR5-antagonists.

Original languageEnglish
Pages (from-to)195-206
Number of pages12
JournalNew Microbiologica
Volume33
Issue number3
Publication statusPublished - Jul 2010

    Fingerprint

Keywords

  • Genotypic tropism testing
  • HIV
  • Trafile
  • Tropism
  • V3 loop

ASJC Scopus subject areas

  • Microbiology (medical)
  • Medicine(all)

Cite this

Svicher, V., D'Arrigo, R., Alteri, C., Andreoni, M., Angarano, G., Antinori, A., Antonelli, G., Bagnarelli, P., Baldanti, F., Bertoli, A., Borderi, M., Boeri, E., Bonn, I., Bruzzone, B., Callegaro, A. P., Cammarota, R., Canducci, F., Ceccherini-Silberstein, F., Clementi, M., ... Perno, C. F. (2010). Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: Results from the OSCAR Study Group. New Microbiologica, 33(3), 195-206.